Sobi ranked No. 1 globally in rare disease corporate reputation, according to PatientView’s latest survey
The annual ‘Corporate Reputation of Pharma’ survey gives patient-advocacy groups an opportunity to comment on, and evaluate, the pharma industry’s performance. Companies are ranked against their peers. ‘The Corporate Reputation of Pharma — Rare-Disease Edition 2024’, shares the perspective of 518 rare disease patient groups from 58 countries, collectively representing the voices of over 2.4 individuals living with rare conditions.
In its first-ever inclusion in the Corporate Reputation of Pharma – Rare Disease report, Sobi was ranked No.1 among 31 global pharmaceutical companies by rare disease patient groups.
Patient groups working with Sobi highlighted the company’s strengths in several key areas:
- Patient-centered approach and collaboration: No.1 in patient centricity, No.1 in patient group relationships, No.1 in services beyond the pill, No.6 in engagement in R&D
- Quality and safety: No. 1 in patient safety, No.1 in transparency of pricing, data and funding, No. 2 in products of benefit
- Access and information: No.1 in patient information, No.2 in access to medicines, No. 2 in integrity
“We are honoured to be No.1 in the report. This recognition reflects our long-standing commitment to people living with rare diseases. Through our Unite4Rare program, we continue to listen, collaborate and co-create solutions with patient communities to make a meaningful difference in the lives of those affected by rare diseases. We are grateful to all who participated in the survey. Their insights inspire us every day”, says Giampiero Marra, VP, Global Patient Engagement and Communication Lead at Sobi.
Looking Ahead: Strengthening the Journey Together
Being recognized in the report is both an honour and a call to action. Sobi remains committed to the Unite4Rare pillars:
- Connect: Connect deeply with patient communities worldwide, including those that are typically underserved.
- Nurture: Partner with truly representative patient organisations in a sustainable, ethical way that helps them thrive.
- Collaborate: Facilitate meaningful and inclusive involvement of patients in medicine development and the patient’s journey.
- Innovate: Create an environment that enables engagement with patients through innovation and forward-looking solutions.
Learn more about Sobi’s commitment to patients
Read more about Unite4Rare here
About the Survey:
- The annual ‘Corporate Reputation of Pharma’ survey gives patient-advocacy groups an opportunity to comment on, and evaluate, the pharma industry’s performance. Companies are ranked against their peers. ‘The Corporate Reputation of Pharma — Rare-Disease Edition’, shares the perspective of 518 rare disease patient groups, focusing on the year 2024.
- The annual surveys are conducted by “PatientView” which is a UK-based research, publishing, and consultancy group, created out of the belief that the views of patients should be considered in all important healthcare decisions.
* Source: PatientView-Press-Release-Corp-Rep-Pharma-Rare-Diseases-2024.pdf
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.
Every day, we work actively to find better ways to understand and meet patient needs.
- About
- Therapeutic areas
- Medicines
- Stories
- Sustainability
- Investors
- Media
- Careers
- English
- Swedish